| Fri, 23 Jul 2021 18:46:36: | AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says
|
| Fri, 23 Jul 2021 15:37:08: | Lumen plots site at nearby Seattle bakery as it ramps up production of algae-based biologics
|
| Fri, 23 Jul 2021 13:25:54: | Takeda lays out $126M to tap robotics, virtual reality and more at California production site
|
| Fri, 23 Jul 2021 09:04:51: | Fierce Pharma Asia—Junshi's mRNA JV; Novartis' China business; Roche's Ronapreve COVID nod in Japan
|
| Thu, 22 Jul 2021 20:32:45: | J&J’s COVID-19 shot scores safety backing from CDC experts but booster need left for FDA
|
| Thu, 22 Jul 2021 15:25:00: | Biogen execs blame critics, the media for spurring 'misinformation' as Aduhelm launch lags expectations
|
| Thu, 22 Jul 2021 12:12:06: | Trade group trio raises drug shortage alarm as FDA ups its carcinogen testing efforts
|
| Wed, 21 Jul 2021 15:20:10: | Johnson & Johnson eyes $2.5B in COVID vaccine sales as key immunology, oncology meds trounce expectations
|
| Wed, 21 Jul 2021 15:05:53: | AstraZeneca closes mega $39B Alexion buyout despite antitrust fears, making a splash in rare diseases
|
| Wed, 21 Jul 2021 14:34:53: | Is Entresto maker Novartis scared of Jardiance's landmark heart failure win? Not really, exec says
|
| Wed, 21 Jul 2021 13:42:49: | Teva taps new North American commercial chief as key meds Ajovy, Austedo lag their rivals
|
| Wed, 21 Jul 2021 13:16:29: | Catalent makes a $100M splash to add biologics drug substance firepower at Italian plant
|
| Wed, 21 Jul 2021 11:24:57: | Otezla maker Amgen challenges patient groups to help fix long-lasting psoriasis treatment gaps
|
| Tue, 20 Jul 2021 21:09:14: | Albireo's rare liver disease drug Bylvay scores back-to-back approvals in U.S., Europe
|
| Tue, 20 Jul 2021 15:28:41: | Alexion's new blockbuster Ultomiris keeps gaining steam as $39B AstraZeneca deal looms
|
| Tue, 20 Jul 2021 15:23:50: | Scandal aside, Biogen's Aduhelm sales set to reach $1B next year and $6B+ by 2025: analysts
|
| Tue, 20 Jul 2021 13:18:14: | Pfizer yanks 12 Chantix lots on carcinogen concerns after pausing global shipments last month
|
| Mon, 19 Jul 2021 15:24:57: | High-profile Biogen ads hype early Alzheimer's detection as hospitals reject Aduhelm prescriptions
|
| Mon, 19 Jul 2021 15:07:22: | BioNTech makes a splash in cell therapy with purchase of factory, R&D platform from Gilead's Kite
|
| Mon, 19 Jul 2021 13:40:50: | Kadmon eyes $15.5K pricetag and August debut for new transplant rejection med Rezurock
|
| Fri, 16 Jul 2021 21:45:08: | Eli Lilly opens Olympic Games with first corporate ad—and a reality check on the state of the U.S. health system
|
| Fri, 16 Jul 2021 19:33:55: | Lyme diagnostic maker Quidel pushes rapid testing in summer camp-focused campaign
|
| Fri, 16 Jul 2021 19:24:54: | Kadmon's Rezurock scores surprise FDA nod in chronic graft-versus-host-disease
|
| Fri, 16 Jul 2021 18:36:35: | Johnson & Johnson takes to Twitter to expand its network of storytelling patients
|
| Fri, 16 Jul 2021 18:00:39: | Merck KGaA’s U.S. unit launches first-ever TV ad with MS drug Mavenclad in the spotlight
|
